{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:20:29Z","timestamp":1783002029819,"version":"3.54.5"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of insulin degludec\/liraglutide (IDegLira) compared with 50\u2009U insulin degludec (degludec) or less in Japanese individuals with type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this 26\u2010week, double\u2010blind, multicentre, treat\u2010to\u2010target trial, Japanese individuals with T2D that was uncontrolled with basal or pre\u2010mix insulin (20\u201350\u2009units) were randomized (1:1) to receive IDegLira or degludec, both with metformin. The maximum dose was 50 dose steps (IDegLira) or 50\u2009units (degludec). The primary endpoint was change from baseline in HbA1c with IDegLira vs degludec after 26\u2009weeks of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 210 Japanese individuals were randomized to IDegLira or degludec and completion rates were 100% and 93%, respectively. IDegLira was superior to degludec with respect to change from baseline in HbA1c: estimated treatment difference (ETD) (95% confidence interval), \u221213.98\u2009mmol\/Mol (\u221216.41; \u221211.55);\n                      <jats:italic>P<\/jats:italic>\n                      &lt;\u20090.0001. The change in mean HbA1c was from 70.6 by \u221221.3\u2009mmol\/Mol with IDegLira and from 70.1 by \u22127.1\u2009mmol\/Mol with degludec. Mean change in body weight was \u22120.7 kg with IDegLira and 0.7 kg with degludec: ETD (95% CI) \u22121.41\u2009kg (\u22122.26; \u22120.56);\n                      <jats:italic>P<\/jats:italic>\n                      =\u20090.0012. Mean daily total insulin dose was significantly lower with IDegLira (37.6 U) as compared to that with degludec (41.2 U) at Week 26. Overall rates of severe or blood glucose\u2010confirmed hypoglycaemia and adverse events were comparable between treatment groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IDegLira provided superior reductions in HbA1c compared with \u226450\u2009U degludec, with weight loss and similar hypoglycaemia rates and no unexpected safety or tolerability issues. These results suggest that this treatment could be an attractive intensification option for Japanese subjects with T2D that was uncontrolled with basal or pre\u2010mixed insulin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13859","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:06:01Z","timestamp":1566173161000},"page":"2694-2703","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Superior HbA1c control with the fixed\u2010ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50\u2009units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double\u2010blind, randomized trial"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5961-1816","authenticated-orcid":false,"given":"Hirotaka","family":"Watada","sequence":"first","affiliation":[{"name":"Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuka","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Diabetes\/Endocrinology\/Lifestyle\u2010related Disease Takatsuki Red Cross Hospital  Takatsuki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhisa","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Division of Internal Medicine Shinshu University School of Medicine  Matsumoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bue Ross","family":"Agner","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Nishida","sequence":"additional","affiliation":[{"name":"Novo Nordisk Pharma Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattis","family":"Ranthe","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Department of Internal Medicine Aichi Medical University School of Medicine  Nagakute Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Federation ID. IDF Atlas 8th Edition: Japan country report.http:\/\/reports.instantatlas.com\/report\/view\/846e76122b5f476fa6ef09471965aedd\/JPN. Accessed March 4 2019."},{"key":"e_1_2_9_3_1","first-page":"36","article-title":"Trends in the epidemiology of patients with diabetes in Japan","volume":"53","author":"Morimoto A","year":"2010","journal-title":"Japan Med Assoc J."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0213-8"},{"key":"e_1_2_9_5_1","first-page":"698","article-title":"Epidemiology of diabetes","volume":"42","author":"Forouhi NG","year":"2014","journal-title":"Medicine (Abingdon)."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.726"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0395-3"},{"key":"e_1_2_9_8_1","unstructured":"SocietyJD. Treatment guide for diabetes.2016.http:\/\/www.fa.kyorin.co.jp\/jds\/uploads\/Treatment_Guide_for_Diabetes_2016-2017.pdf. Accessed March 2019."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2016-000294"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198160"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13132"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01628.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2014.0330"},{"key":"e_1_2_9_14_1","unstructured":"Novo Nordisk. Xultophy\u00ae summary of product characteristics.2018.https:\/\/www.medicines.org.uk\/emc\/product\/3469. Accessed March 4 2019."},{"key":"e_1_2_9_15_1","unstructured":"Novo Nordisk. Xultophy\u00ae 100\/3.6 Prescribing information.https:\/\/www.novo-pi.com\/xultophy10036.pdf. Accessed March 2019."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1252"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1114"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-127-OR"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2337\/cd17-0064","article-title":"Safety and efficacy of insulin Degludec\/Liraglutide (IDegLira) and insulin glargine U100\/Lixisenatide (iGlarLixi), two novel co\u2010formulations of a basal insulin and a glucagon\u2010like Peptide\u20101 receptor agonist, in patients with diabetes not adequately controlled on oral antidiabetic medications","volume":"36","author":"Wysham CH","year":"2018","journal-title":"Clin Diabetes."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd17-0065"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-3010"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61267-7"},{"issue":"1","key":"e_1_2_9_25_1","first-page":"A289","article-title":"Converting to insulin degludec\/liraglutide (IDegLira) is efficacious regardless of pretrial insulin dose in patients with type 2 diabetes (T2D) uncontrolled on insulin glargine U100 (IGlar)","volume":"66","author":"Meneghini LF","year":"2017","journal-title":"Diabetes"},{"issue":"1","key":"e_1_2_9_26_1","article-title":"Efficacy of IDegLira vs. basal\u2010bolus therapy in subjects with type 2 diabetes in DUAL VII by baseline characteristics","volume":"67","author":"Billings LK","year":"2018","journal-title":"Diabetes"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001986"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12498"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13859","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13859","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13859","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:39:23Z","timestamp":1761863963000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1111\/dom.13859"],"URL":"https:\/\/doi.org\/10.1111\/dom.13859","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.13859\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v2\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13859\/v2\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"2019-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}